The provider of plant-based ingredients will present recently launched multi-compendial materials for upstream and downstream biopharmaceutical applications.
Roquette announced that it recently launched low endotoxin Kleptose BioPharma hydroxypropyl betacyclodextrin grades of hydroxypropyl β-cyclodextrins for protein stability and Dextrose Anhydrous BioPharma for cell-culture solutions for upstream and downstream biopharma applications.
According to the company, these solutions are supported by vertically integrated manufacturing, International Conference on Harmonization Q7 quality standards, and a fiber-free supply chain. Roquette recently expanded its research and development and customer technical service teams to include facilities in Singapore’s Biopolis international research and development center to develop these products.
“Now our deep expertise in formulation and applications science enables us to provide customers with even more localized project support around the world and in-depth training on-site,” Roquette stated in an Aug. 27, 2018 company press release. “Laboratory and pilot equipment at these facilities help customers address their technical and innovation challenges.”
Additionally, the company will also showcase recently acquired Microcrystalline Cellulose products and other excipients and hold 360-degree virtual experience recreation tours at stand 8F30 at CPhI in Madrid, Spain, taking place Oct. 9–11, 2018.
Source: Roquette
Benuvia Granted GMP Certification by Brazil National Health Surveillance Agency
March 14th 2025The certification allows Benuvia to produce pharmaceutical products for companies, either local to Brazil or international, that may be looking for compliant and high-quality production capabilities in the Brazilian pharmaceutical market.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.